• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 43
  • 33
  • 4
  • 1
  • 1
  • 1
  • Tagged with
  • 91
  • 41
  • 34
  • 27
  • 26
  • 25
  • 21
  • 21
  • 19
  • 19
  • 18
  • 17
  • 17
  • 16
  • 14
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
1

Molecular mechanisms of tumor development in hyperparathyroidism /

Farnebo, Filip, January 1900 (has links)
Diss. (sammanfattning) Stockholm : Karol. inst. / Härtill 8 uppsatser.
2

Oral manifestations of systemic hyperparathyroidism this thesis was submitted in fulfillment ... for the degree of Master of Science in Periodontics ... /

Padbury, Allan Dale. January 2004 (has links)
Thesis (M.S.)--University of Michigan, 2004. / Includes bibliographical references.
3

Evaluation of renal bone disease in transplant recipients and related conditions

Parker, Cornelle R. January 2000 (has links)
No description available.
4

Surgery for Renal Hyperparathyroidism : Experience of 640 Cases

UCHIDA, KAZUHARU, TANAKA, YUJI, TOMINAGA, YOSHIHIRO, TAKAGI, HIROSHI 03 1900 (has links)
No description available.
5

Studies of tumourigenesis in the multiple endocrine neoplasia type 1 and hyperparathyroidism-jaw tumour syndromes

Walls, Gerard V. January 2011 (has links)
No description available.
6

Novel Use of Calcimimetic Activity to Diagnose Primary Hyperparathyroidism in a Patient With Persistently Low-Normal Parathyroid Hormone Level

Bandaru, Sindhura, Manthri, Sukesh, Nallala, Deepika, Mamillapalli, Chaitanya K., Jakoby, Michael G. 23 July 2020 (has links)
Primary hyperparathyroidism (PHPT) is the most common etiology of hypercalcemia in the ambulatory setting and usually presents with an intact parathyroid hormone (PTH) level that is elevated or inappropriately near the upper limit of the laboratory reference range. However, PHPT with low-normal PTH level is reported in the peer-reviewed literature, and this atypical presentation may delay diagnosis of PHPT. We present a case of PHPT with persistently low-normal PTH level in which the PTH dependence of hypercalcemia was demonstrated by the response to treatment with the calcimimetic agent cinacalcet.
7

Studies into the effects of non-calcaemic vitamin D sterols on bone cells

McIntyre, Christopher William January 2001 (has links)
No description available.
8

Efeito da associação do carbonato de magnésio com acetato de cálcio (OSVAREN®) no controle do fósforo, no hiperparatireoidismo secundário e no remodelamento ósseo em ratos urêmicos / Magnesium carbonate/calcium acetate (Osvaren®) association effects in phosphorus, secondary hyperparathyroidism and bone turnover in uremic rats

Ferrari, Guaraciaba Oliveira 27 July 2012 (has links)
Introdução: O quelante de fósforo (P) Osvaren® foi lançado recentemente no mercado internacional para tratamento da hiperfosfatemia nos pacientes com Doença Renal Crônica (DRC). Não existem estudos experimentais com esta medicação. Objetivo: Avaliar a ação deste quelante no tratamento do Distúrbio Mineral e Ósseo (DMO) de ratos com DRC induzida por adenina e por nefrectomia 5/6 (NX5/6). Métodos: Experimento 1: Durante 4 semanas, ratos Wistar receberam dieta com adenina [2 semanas (0,75%); 2 semanas (0,50%)] e então foram divididos em 3 grupos para receber dieta padrão (grupo DRC); dieta padrão com 3% de Acetato de Cálcio (grupo Ca); e dieta padrão com 3% de Osvaren® (grupo CaMg). Um grupo Controle (função renal normal) recebeu a dieta padrão durante todo o estudo. Ao final de cinco semanas de tratamento os animais foram sacrificados. Experimento 2: ratos da mesma espécie foram submetidos à NX5/6, divididos em grupos como no experimento 1 para receberem os quelantes de P imediatamente após a nefrectomia, e sacrificados após 9 semanas. Nos dois experimentos foram coletados soro, fêmures, aortas e paratireóides para análise bioquímica, histomorfometria óssea, pesquisa de calcificação vascular (CV) e imunohistoquímica de paratireóides, respectivamente. Resultados: Experimento 1: Os animais que receberam adenina apresentaram níveis maiores de creatinina, PTH, P e magnésio (Mg) que os do grupo Controle. Os quelantes de P reduziram a fração de excreção de P (FeP), mas não o P sérico, enquanto os níveis de PTH, FGF23 e calcitriol diminuíram de forma não significativa nos grupos tratados. O Mg sérico foi significativamente maior no grupo CaMg, enquanto maior calciúria, mais CV e menor marcação pelo PCNA nas paratireóides foram observadas no grupo Ca. Os animais que receberam adenina apresentaram doença óssea mista e ambos os quelantes de P melhoraram a remodelação, mas favoreceram a um acúmulo ainda maior de osteóide. Experimento 2: Da mesma forma que no experimento 1, o animais submetidos à NX5/6 evoluíram com uremia, e os efeitos dos quelantes no PTH, na CV e nas paratireóides foram similares. No entanto, o grupo CaMg apresentou mortalidade de 54% (vs 20% no grupo Ca), além de retardo na mineralização óssea. Conclusão: O tipo de nefropatia pode ter influência no efeito do quelante de P Osvaren®, já que o acúmulo de Mg provavelmente foi o responsável pela maior mortalidade e déficit de mineralização observados no experimento 2. Em relação ao efeito como quelante de P, o Osvaren® foi equivalente ao acetato de cálcio, mas este último está associado a maior sobrecarga de cálcio e a CV. O acúmulo de osteóide observado em ambos os experimentos parece ser o preço pago pela reduzida absorção intestinal de P favorecida pelos quelantes no hiperpatireoidismo secundário severo e esse efeito deveria ser avaliado em pacientes em diálise / Introduction: Osvaren® is a phosphate (P) binder that has been recently introduced for Chronic Kidney Disease (CKD) patients therapy. However, it has not been tested in experimental models yet. Aims: To study Osvaren® effects on mineral and bone metabolism in CKD experiment models. Methods: Experiment 1: For 4 weeks (wk), rats were fed normal chow or an adenine-enriched diet (0,75% for 2 wks; 0,50% for 2 wks). After that, adenine was discontinued and rats were divided into 3 groups: Ca (3% calcium acetate); CaMg (3% Osvaren®) and CKD (normal diet/untreated). A control group, with normal renal function was also studied. After 5 wks of therapy, animals were sacrificed. Experiment 2: Animals underwent 5/6 nephrectomy, and were submitted to different P binders treatment as in experiment 1 and then sacrificed 9 weeks after surgery. We performed biochemical and histomorphometric analyses, parathyroid PCNA imunohistochemistry, as well as Von Kossa staining and calcium content of aortic sections. Results: Experiment 1: Higher creatinine, PTH, FGF-23, P and Mg were found in all adenine-fed rats. P binders did not reduce serum P but decreased fractional excretion of P (FeP) and tended to reduce PTH, FGF23 and calcitriol levels. In the CaMg group, Mg was slightly elevated, whereas Ca group had greater urinary calcium as well as vascular calcification and smaller parathyroid PCNA staining. Adenine-fed rats presented features of mixed bone disease and P binders therapy was able to decrease bone resorption, but was associated with an osteoid accumulation. Experiment 2: As in experiment 1, nephrectomized rats were uremic and P binder effects on PTH, vascular calcification and parathyroid were very similar, except for the mortality rate, that was higher in CaMg group (54% vs 20% in Ca group). An increase in mineralization lag time was also found in CaMg group. Conclusions: Osvaren® may cause different effects on different types of nephropathy, as in experiment 2 the Mg was probably the responsible for higher mortality as well as for bone mineralization defect. In terms of P binding efficacy, Osvaren® was equivalent to calcium acetate, but the last one caused calcium overload and vascular calcification. The osteoid accumulation is probably related to the decrease in intestinal P absorption caused by the P binders in these models of secondary hyperparathyroidism. These effects should also be evaluated in dialysis patients
9

The Clinical Investigation of 1α-OH-D3 on Hemodialized Patients

SAKAMOTO, NOBUO, KAWAHARA, HlROHlSA, OKURA, TAKANOBU, ASAI, KANlCHI, WATANABE, YUZO 03 1900 (has links)
No description available.
10

Major Surgery in Patients Undergoing Hemodialysis

KAWAHARA, KATSUHlKO, KANO, TADAYUKI, KAWAI, MACHIO, TOMINAGA, YOSHIHIRO, YASUE, MITSUNORI, MORIMOTO, TAKESHI, YAMADA, NOBUO, UCHIDA, KAZUHARU, TAKAGI, HIROSHI 03 1900 (has links)
No description available.

Page generated in 0.0931 seconds